4-氨基-2-羟基-5-硝基苯甲酸 | 197584-93-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-2-羟基-5-硝基苯甲酸
• 英文名称: 4-amino-2-hydroxy-5-nitrobenzoic acid
• 英文别名: 4-Amino-2-hydroxy-5-nitro-benzoesaeure
• CAS: 197584-93-3
• 化学式: C₇H₆N₂O₅
• 分子量: 198.135
• InChiKey: OXSQGWPEUHGSSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-氨基-2-羟基-5-硝基苯甲酸 在 sodium carbonate 、 溶剂黄146 、 锌 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 12.5h， 生成 methyl 4,5-diamino-2-hydroxybenzoate
  参考文献：
  名称：

  结核分枝杆菌 磷酸酶新型，选择性和药物样抑制剂的多样性导向合成†

  摘要：

  分枝杆菌蛋白酪氨酸磷酸酶B（mPTPB）是结核病（TB）的潜在药物靶标。使用mPTPB的小分子抑制剂可以克服新出现的TB耐药性。我们使用多样性导向的合成（DOS）策略，成功开发了基于水杨酸的类药物mPTPB抑制剂，其IC 50为2μM，其特异性是许多人PTP的20倍以上，使其成为抗PPT的优秀先导分子-TB药物发现。此外，DOS生成的双环水杨酸也是获得靶向其他PTP抑制剂的有前途的起点。

  DOI：

  10.1039/c4md00099d
• 作为产物：
  描述：

  4-苯酰胺-2-羟基苯甲酸 在 sodium hydroxide 、 硫酸 、 硝酸 作用下， 生成 4-氨基-2-羟基-5-硝基苯甲酸
  参考文献：
  名称：

  van der Stelt et al., Arzneimittel-Forschung/Drug Research, 1954, vol. 4, p. 544,546

  摘要：

  DOI：

文献信息

• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20140128392A1

  公开（公告）日：2014-05-08

  Disclosed herein are new heterocyclic compounds of Formula IIa: and compositions thereof, and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的Formula IIa的杂环化合物及其组合物，以及它们作为治疗疾病的药物的应用。还提供了在人类或动物主体中抑制PAS激酶（PASK）活性的方法，用于治疗糖尿病等疾病。
• [EN] CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS MACROCYCLIQUES ENTIÈREMENT SYNTHÉTIQUES, À CONFORMATION CONTRAINTE
  申请人：POLYPHOR AG

  公开号：WO2011015241A1

  公开（公告）日：2011-02-10

  Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT2B (5-HT2B receptor), and on the prostaglandin F2 • receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.

  构象受限、空间定义的12-30元大环环系统(I型)由三个不同的构建模块组成：芳香模板a、构象调节剂b和间隔基团c，详细描述在说明书和专利要求中。I型大环可通过并行合成或组合化学方法轻松制备。它们设计用于与特定生物靶点相互作用。特别是，它们在胃动素受体(MR受体)、5-羟色胺受体亚型5-HT2B(5-HT2B受体)和前列腺素F2•受体(FP受体)上显示激动或拮抗活性。因此，它们潜在用于治疗胃肠道低动力障碍，如糖尿病性胃轻瘫和便秘型肠易激综合征；中枢神经系统相关疾病，如偏头痛、精神分裂症、精神病或抑郁症；眼压增高，如青光眼和早产。
• CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS
  申请人：Obrecht Daniel

  公开号：US20120270881A1

  公开（公告）日：2012-10-25

  Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y 1 , as modulators of the serotonin receptor of subtype 5-HT 2B , as blockers of the voltage-gated potassium channel K v 1.3 and as inhibitors of the β-catenin-dependent “canonical” Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.

  具有结构限制的、空间定义的12-30环的大环系统Ia和Ib由三个不同的分子部分构成：模板A、构象调节剂B和桥C。这些大环Ia和Ib可以通过并行合成或溶液中或固相上的组合化学来轻松制备。它们被设计用于与各种特定的生物靶标类相互作用，例如对G蛋白偶联受体（GPCRs）、离子通道和信号转导途径的激动或拮抗活性。特别地，这些大环作为莫蒂林受体的拮抗剂、FP受体和嘌呤受体P2Y1的调节剂、5-HT2B亚型的5-羟色胺受体的调节剂、电压门控钾通道Kv1.3的阻断剂以及β-连环蛋白依赖的“经典”Wnt途径的抑制剂。因此，它们显示出作为各种疾病药物的巨大潜力。
• 4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof
  申请人：LEE AN-RONG

  公开号：US20120101157A1

  公开（公告）日：2012-04-26

  Disclosed are 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives and manufactures thereof. The 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives are presented by formula (I): wherein R 1 group is H, CH 3 , or C 2 H 5 ; R 2 group is H, or Br; R 3 group is CH 3 , or C 3 H 7 ; and R 4 group is H, or C(═NH)—NH 2 . 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives provided here were non-toxic to MDCK cells, particularly compounds 6 a , 6 b , 6 c , 6 e , 6 f , 7 a , 7 b and 8 had better anti-H1N1 activity. In the future, these compounds can be used to focus on viral neuraminidases as targets to develop effective anti-influenza drugs.

  本文披露了4,5-二氨基-3-卤代-2-羟基苯甲酸衍生物及其制备方法。所述4,5-二氨基-3-卤代-2-羟基苯甲酸衍生物由下式（I）表示：其中R1基团为H、CH3或C2H5；R2基团为H或Br；R3基团为CH3或C3H7；R4基团为H或C(═NH)—NH2。本文提供的4,5-二氨基-3-卤代-2-羟基苯甲酸衍生物对MDCK细胞无毒，特别是化合物6a、6b、6c、6e、6f、7a、7b和8具有更好的抗H1N1活性。未来，这些化合物可以用于将病毒神经氨酸酶作为靶点，开发有效的抗流感药物。
• Heterocyclic compounds for the inhibition of PASK
  申请人：BioEnergenix, LLC

  公开号：US09370522B2

  公开（公告）日：2016-06-21

  Disclosed herein are new heterocyclic compounds having structural Formula IIa and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了具有结构式IIa的新杂环化合物及其组合物，并将其应用于治疗疾病的制药。还提供了抑制人类或动物体内PAS激酶（PASK）活性的方法，用于治疗糖尿病等疾病。